# David A. Palma

Source: https://onco.cc/people/david-palma/  
OnCo record `david-palma` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led SABR-COMET, the trial that showed treating a few metastases with high-dose radiation can prolong survival.

## Summary

David Palma (London, Ontario) was principal investigator of SABR-COMET, the randomised phase 2 trial showing stereotactic ablative radiotherapy to all sites of oligometastatic disease improves overall survival, which launched the oligometastatic treatment paradigm and the SABR-COMET-3 and -10 phase 3 trials. He also studies treatment de-escalation in head and neck cancer and hosts a widely used teaching channel.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: radiotherapy; oligometastatic; sbrt
- Role: Radiation Oncologist, London Health Sciences Centre; Professor, Western University
- Specialisms: Oligometastatic disease; Stereotactic radiotherapy; Pragmatic trial design

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Palma%20DA%5BAuthor%5D%20SABR-COMET

## Connected records

- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- institutions: [Verspeeten Family Cancer Centre, London Health Sciences Centre](https://onco.cc/institutions/lhsc-verspeeten/)
- terms: [De-escalation, escalation and response-adapted therapy](https://onco.cc/terms/de-escalation/), [Oligometastatic disease](https://onco.cc/terms/oligometastatic/), [Radiotherapy](https://onco.cc/terms/radiotherapy/), [Stereotactic body radiotherapy (SBRT / SABR)](https://onco.cc/terms/sbrt-term/)

---
JSON: https://onco.cc/api/v1/entities/david-palma.json